Literature DB >> 21561356

Advances in pancreatic neuroendocrine tumor treatment.

Daniel Castellano, Enrique Grande, Jorge Barriuso.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21561356     DOI： 10.1056/NEJMc1102746

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis.

Authors:  Jaume Capdevila; Isabel Sevilla; Vicente Alonso; Luís Antón Aparicio; Paula Jiménez Fonseca; Enrique Grande; Juan José Reina; José Luís Manzano; Juan Domingo Alonso Lájara; Jorge Barriuso; Daniel Castellano; Javier Medina; Carlos López; Ángel Segura; Sergio Carrera; Guillermo Crespo; José Fuster; Javier Munarriz; Pilar García Alfonso
Journal:  BMC Cancer       Date:  2015-07-04       Impact factor: 4.430

2.  Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study.

Authors:  Marta Martín-Richard; Bartomeu Massutí; Eva Pineda; Vicente Alonso; Maribel Marmol; Daniel Castellano; Emilio Fonseca; Antonio Galán; Marta Llanos; Maria Angeles Sala; Carlos Pericay; Fernando Rivera; Javier Sastre; Angel Segura; Maria Quindós; Pascal Maisonobe
Journal:  BMC Cancer       Date:  2013-09-20       Impact factor: 4.430

3.  Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial.

Authors:  Enrique Grande; Cristina Rodriguez-Antona; Carlos López; Teresa Alonso-Gordoa; Marta Benavent; Jaume Capdevila; Alex Teulé; Ana Custodio; Isabel Sevilla; Jorge Hernando; Pablo Gajate; Javier Molina-Cerrillo; Juan José Díez; María Santos; Javier Lanillos; Rocío García-Carbonero
Journal:  Oncologist       Date:  2021-07-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.